Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis?

Current Opinion in Rheumatology

Volumn 15, Issue 3, 2003, Pages 185-192

  Cannella, Amy C ^a,c   O'Dell, James R ^b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^c Division of Rheumatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AUROTHIOMALATE; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; PENICILLAMINE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

ALGORITHM; APLASTIC ANEMIA; CLINICAL TRIAL; DEMYELINATING DISEASE; DRUG COST; DRUG INDUCED DISEASE; DRUG MEGADOSE; EYE TOXICITY; HUMAN; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PRIORITY JOURNAL; RETINA DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN MANIFESTATION;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONG-TERM CARE; MALE; METHOTREXATE; ORGANOGOLD COMPOUNDS; PROGNOSIS; RESEARCH; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0038746822     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200305000-00003     Document Type: Review

References (68)

1. Pincus T, Callahan LF, Sale WG, et al.: Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984, 27:864-872.
2. Gabriel SE: The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001, 27:269-281.
3. McInnes IB: Rheumatoid arthritis: from bench to bedside. Rheum Dis Clin North Am 2001, 27:373-387. This review details the basic science of inflammation in the rheumatoid synovium and how it relates to engineering new biologic therapies.
4. Van der Heide A, Jacobs J, Bijlsma J, et al.: The effectiveness of early treatment with "second-line" antirheumatic drugs: a randomized controlled trial. Ann Intern Med 1996, 124:699-707.
5. Egsmose C, Lund B, Borg G, et al.: Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow-up of a prospective double blind placebo controlled study. J Rheumatol 1995, 22:2208-2213.
6. Bensen WG, Bensen W, Adachi JD: Back to the future: the pyramids of rheumatoid arthritis. J Rheumatol 1997, 24:1023-1027.
7. O'Dell J, Haire C, Erikson N, et al.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996, 334:1287-1291.
8. Calguneri M, Pay S, Caliskaner Z, et al.: Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheum 1999:17:699-704.
9. Boers M, Verhoeven A, Marusse H, et al.: Randomized comparison of combined step-down prednisolone, methothrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997, 350:309-138.
10. Mottonen T, Hannonsen P, Leiralalo-Repo M, et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial. Lancet 1999;353:1568-1573.
11. Elliott J, Maini R, Reldmann M, et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (eA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1101-1110.
12. Maini R, Breedveld F, Kalden J, et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
13. Moreland L, Baumgartner S, Schiff M, et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997, 337:141-147.
14. Weinblatt M, Kremer J, Bankgurst A, et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259.
15. Keystone E, Weinblatt M, Furst D, et al.: The ARMADA trial: a double-blind placebo controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2E7) in patients with active IRA on methotrexate (MTX). Arthritis Rheum 2001, 44:PS213.
16. Breshnihan B, Alvaro-Garcia JM, Cobby M, et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41:2196-2204.
17. Choy EHS, Isenberg DA, Garrood T, et al.: Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46:3143-3150.
18. Kremer J, Westhovens R, Leon M, et al.: A phase 2B multi-center, randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of two different doses of CTLA4-lg administered intravenously to subjects with active rheumatoid arthritis while receiving methotrexate. Arthritis Rheum 2002, 46:S203.
19. Edwards JCW, Szczepanski L, Szechinski J, et al.: Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo-controlled trial in patients with rheumatoid arthritis. Arthritis Rheum 2002, 46:S197.
20. Tsakonas E, Fitzgerald AA, Fitzcharles MA, et al.: Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year follow-up on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 2000, 27:623-629.
21. Lard LR: Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: results of two meta-analysis. Am J Med 2001, 111:446-451.
22. Felson DT, Anderson JJ, Meenan RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two met analyses. Arthritis Rheum 1990, 33;1449-1461.
23. Pincus T, Marcum SB, Callahan LF: Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: Second line drugs and prednisone. J Rheumatol 1992, 19:1885-1894.
24. Wolfe F, Hawley DJ, Cathey MA: Termination of a slow acting antirheumatic therapy in rheumatoid arthritis: a 14 year prospective evaluation of 1017 con-secutive starts. J Rheumatol 1990, 17:994-1002.
25. Mikuls T, O'Dell JR: The treatment of rheumatoid arthritis: current trends in therapy. Arthritis Rheum 1999, 42:S79.
26. Williams HJ, Willkens RF, Samuelson CO Jr, et al.: Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985, 28:721-730.
27. Kremer JM: Safety, efficacy and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: follow-up after mean of 13.3 years. Arthritis Rheum 1997, 40:984-985.
28. O'Dell JR: Methotrexate use in rheumatoid arthritis. Rheum Dis North Am 1997, 23:779-796.
29. Morgan S, Baggott J, Vaughn W, et al.: Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo controlled trial. Ann Intern Med-1994, 121:833-841.
30. Weinblatt M: Methotrexate (MTX) in rheumatoid arthritis (IRA): a 5-year multi prospective trial. Arthritis Rheum 1993, 36:S3.
31. Svartz N: Salazopyrin, a new sulfanilamide preparation. Acta Med Scand 1942, 110:577.
32. Herman K, Leys A, Spileers W: (Hydroxy)-chloroquine retinal toxicity: two case reports and safety guidelines. Bull Soc Belge Opthalmol 2002, 284:21-29. Two case reports of toxicity from hydroxychloroquine and chloroquine are given, with strategies for reducing toxicity.
33. Smolen JS, Kalden JR, Scott DL, et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized multicenter trial. Lancet 1999, 353:259-266.
34. Strand V, Cohen S, Schiff M, et al.: For the Leflunomide Rheumatoid Arthritis Investigators Group. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999, 159:2542-2550.
35. Rau R, Herborn G, Menninger H, et al.: Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold: extension of a one-year double-blind study in 174 patients. Rheumatology 2002, 41:196-204. This study compared radiographic outcomes in high-dose gold and methotrexate and found that both have similar radiographic outcomes after 3 years.
36. O'Dell JR, Haire CE, Palmer W, et al.: Treatment of early rheumatoid arthritis with minocycline or placebo. Arthritis Rheum 1997, 40:842-848.
37. O'Dell JR, Paulsen G, Haire CE, et al.: Treatment of early seropositive rheumatoid arthritis with minocycline. Arthritis Rheum 1999, 42:1691-1695.
38. O'Dell JR, Blakely KW, Mallet JA, et al.: Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001, 44:2235-2241.
39. Kirwan JR: The effect of glucocorticoid on joint destruction in rheumatoid arthritis. N Engl J Med 1995, 333:142-146.
40. Moreland LW, O'Dell JR. Glucocorticoids and rheumatoid arthritis. Arthritis Rheum 2002, 46:2553-2563. This paper reviews the mechanism of action, reported trials, clinical uses and side effects of glucocorticoids in rheumatoid arthritis. Recommendations for the use of glucocorticoids in rheumatoid arthritis are detailed.
41. Simms RW, Kwoh CK, Anderson LG, et al.: Guidelines for monitoring drug therapy in rheumatoid arthritis: American college of rheumatology ad hoc committee on clinical guidelines. Arthritis Rheum 1996, 39:723-731.
42. Kwoh CK, Anderson LG, Greene JM, et al.: Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002, 46:328-346. This comprehensive review article discusses the initial evaluation, diagnosis, and therapy, both pharmacologic and nonpharmacologic, of rheumatoid arthritis. Also detailed are recommendations for prudent monitoring and strategies to reduce drug toxicities.
43. Harris E: The rationale for combination therapy of rheumatoid arthritis based on pathophysiology. J Rheum 1996, 23(suppl 44):2-4.
44. Tugwell P, Pincus T, Yocum D, et al.: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995, 333:137-142.
45. O'Dell J, Nepon B, Haire C, et al.: HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. Ann Rheum Dis 1998, 57:209-213.
46. O'Dell JR, Leff R, Paulsen G, et al.: Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine or a combination of three medications. Arthritis Rheum 2002, 46:1164-1170.
47. Landewe RBM, Boers M, Verhoeven AC, et al.: COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002, 46:347-356.
48. Neva M, Dauppi M, Kautiainen H, et al.: Combination drug therapy retards the development of rheumatoid atlantoaxial subluxations. Arthritis Rheum 2000, 11:2397-2401.
49. O'Dell JR: Anticytokine therapy: a new era in the treatment of rheumatoid arthritis. N Engl J Med 1999, 340:310-312.
50. Lipsky P, Van Der Heide DM, St Clair EW, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group N Engl J Med 2000, 343:1594-1602.
51. Bathon JM, Martin RW, Fleischmann RM, et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1592.
52. Van De Putte LB, Atkins C, Malaise M, et al.: Adalimumab (D2E7) monotherapy in the treatment of patients with rheumatoid arthritis. Arthritis Rheum 2002, 46:S205.
53. Keystone E, Kavanaugh AF, Sharp J, et al.: Adalimumab (D2E7), a fully human anti-tnf-α monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy. Arthritis Rheum 2002, 46:S205.
54. Shanahan JC, St Clair W: Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. Clin Immunol 2002, 103(3 Pt 1 ):231-242.
55. Klippel J: Biologic therapy for rheumatoid arthritis. N Engl J Med 2000, 343:1640-1642.
56. Favalli EG, Sinigaglia L, Varenna M, et al.: Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002, 11:753-755.
57. Shakoor N, Michalska M, Harris CA, et al.: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002, 579-580.
58. Brown LS, Greene MH, Gershon SK, et al.: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002, 46:3151-3158. This article illustrates the importance of postmarketing surveillance and voluntary reporting of adverse events to the FDA.
59. Genovese MC, Bathon JM, Martin RW, et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46:1443-1450.
60. St Clair EW, Wagner CL, Fasanmade AA, et al.: The relation of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:1451-1459.
61. Cohen S, Hurd E, Cush J, et al.: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritis Rheum 2002, 46:614-624.
62. Jiang Y, Genant HK, Watt I, et al.: A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000, 43:1001-1009.
63. Potter T, Mulherin D, Pugh M: Early intervention with disease-modifying therapy for rheumatoid arthritis: where do the delays occur? Rheumatology 2002, 41:953-955.
64. Drug Topics: The Red Book. Montvale, NJ: Medical Economics Co.; 2002.
65. Munster T, Gibbs JP, Shen D, et al.: Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002, 46:1460-1469.
66. Conaghan PG, Quinn MA, O'Connor P, et al.: Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission? Arthritis Rheum 2002, 46:1971-1972.
67. O'Dell JR: Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002, 46:283-285.
68. Garnero P, Landewe R, Boers M, et al.: Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002, 46:2847-2856.